Keith Meister Sells 104,393 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 104,393 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director directly owned 3,500,048 shares of the company’s stock, valued at $508,696,976.32. This represents a 2.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Illumina Stock Performance

NASDAQ ILMN traded down $1.76 during trading on Thursday, reaching $143.24. The company’s stock had a trading volume of 2,006,814 shares, compared to its average volume of 1,636,244. The firm has a 50 day moving average price of $128.31 and a 200 day moving average price of $129.43. Illumina, Inc. has a 12 month low of $78.55 and a 12 month high of $155.53. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $21.67 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the firm posted $0.97 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Illumina

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Elyxium Wealth LLC acquired a new position in Illumina in the 4th quarter valued at approximately $25,000. Board of the Pension Protection Fund acquired a new position in Illumina in the 4th quarter valued at approximately $26,000. Creative Capital Management Investments LLC increased its position in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina during the fourth quarter worth $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina during the fourth quarter worth $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ILMN. Guggenheim upped their price objective on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Royal Bank Of Canada set a $170.00 price objective on shares of Illumina in a research report on Thursday. UBS Group reiterated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Finally, Citigroup upped their price target on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $137.75.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.